Skip to main content

abrocitinib

Generic: ABROCITINIB·Brand: CIBINQO, Cibinqo

abrocitinib: developed by 1 company · 1 FDA decision.

abrocitinib evidence translation

What we can confirm

1 FDA record

What it means

Source-backed records connect abrocitinib to PFE; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could abrocitinib → PFE affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

Development Pipeline (2)
CompanyPhase
PFIZER INC (PFE)Approved
PFIZER INC (PFE)Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants. CIBINQO is a Janus kinase (PFE)FDA ↗
NDA213871Type 1 - New Molecular EntityPriorityOralTablet

Frequently asked questions

Who is developing abrocitinib?

abrocitinib is being developed by PFIZER INC.

What is abrocitinib's latest FDA decision?

The most recent tracked FDA decision for abrocitinib is Approval for 1 INDICATIONS AND USAGE CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants. CIBINQO is a Janus kinase , dated January 14, 2022.